2015 transformative year with focus on developing safe and effective Broad Spectrum Therapeutics for the treatment of serious and life-threatening infections 2016 expected to produce confirmatory data for cochleate technology platform  Topline data from Phase 2a clinical trial with MAT2203 (oral encochleated amphotericin B) expected in 2016  Phase 1 clinical trial for MAT2501 (oral encochleated amikacin) expected to commence in 2016 BEDMINSTER, N.J., March 31, 2016 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, today announced its […]